Zarnovicanova M, Mocikova K
Department of Hematology, F.D. Roosevelt's Hospital, Banska Bystrica, Slovakia.
Bratisl Lek Listy. 2000;101(1):28-30.
Alpha2-antiplasmin is the main inhibitor of plasma fibrinolytic system. An inborn defect of alpha2-antiplasmin was first described by Koie et al. in 1978 in connection with severe haemorrhage syndrome. The authors present a case report of 45 years old woman living in middle Slovakia with severe haemorrhagic syndrome started in childhood (epistaxis, skin and muscle hematomas, appendectomy with 6 weeks recovery, hardly manageable haemorrhage after teeth extractions, menorrhage, metrorrhage). Laboratory tests were negative for platelet function defects and coagulation system defects. Low level of alpha2-antiplasmin activity (10%) was detected with use of synthetic chromogenic substrate method and low amount (2%) with ELISA method. In asymptomatic daughter was decreased level of alpha2-antiplasmin (activity 51%, quantity 32%) detected. On the basis of patient history, laboratory investigations and comparison with published cases the haemorrhagic syndrome is considered to be an inborn homozygous quantitative defect of alpha2-antiplasmin. Detection of the defect in further haemorrhagic and risk situations (including laparotomy, multiple teeth extractions, obstetric surgery) led to following therapeutic measures: careful local care [by procedures], tranexamic acid in sufficient dose [4 g/day in continual i.v. infusion, or 4 x 1 g in 1/hour infusions, 4 x 1 g perorally], in sufficient duration [14 days by procedures]. Therapeutic approach after detection of the defect is efficient. (Tab. 2, Ref. 13.)
α2-抗纤溶酶是血浆纤维蛋白溶解系统的主要抑制剂。1978年,Koie等人首次描述了α2-抗纤溶酶的先天性缺陷与严重出血综合征有关。作者报告了一名居住在斯洛伐克中部的45岁女性病例,该患者自童年起就患有严重出血综合征(鼻出血、皮肤和肌肉血肿、阑尾切除术后恢复6周、拔牙后出血难以控制、月经过多、子宫出血)。实验室检查血小板功能缺陷和凝血系统缺陷均为阴性。使用合成发色底物法检测到α2-抗纤溶酶活性水平较低(10%),采用ELISA法检测到含量较低(2%)。在无症状的女儿中检测到α2-抗纤溶酶水平降低(活性51%,含量32%)。根据患者病史、实验室检查并与已发表病例进行比较,出血综合征被认为是α2-抗纤溶酶的先天性纯合子定量缺陷。在进一步的出血和危险情况下(包括剖腹手术、多次拔牙、产科手术)检测到该缺陷后,采取了以下治疗措施:仔细的局部护理[通过相关操作]、足够剂量的氨甲环酸[持续静脉输注4 g/天,或每小时输注4×1 g,口服4×1 g]、足够的持续时间[通过相关操作持续14天]。检测到缺陷后的治疗方法是有效的。(表2,参考文献13)